The genetically defined myelodysplastic syndrome in the ICC and WHO of MDS with TP53/MDS with bi-allelic TP53 inactivation is diagnosed in the presence of TP53 aberrations (either mutations or deletions) and is justified by its association with a poor prognosis with suboptimal outcomes even with allo-HSCT [46,47]. Here, TP53 is linked to myelodysplastic syndrome.